Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Certolizumab pegol (ATC-Code nach WHO: L04AB05)

Decision signals

First-pass opportunity review

These signals are calculated from the indexed fields. They help prioritize a review but do not replace eligibility checks in the official procurement documents.

Timing signal

608 days to indexed deadline

30 June 2028

Indexed data completeness

86%

Based on seven decision fields

Official title coverage

7 languages

Preserved from source-supplied versions

Classification signal

33600000

Medical equipment, pharmaceuticals and personal care products

90-day market activity

455 related notices

106 buyers in Germany / Pharma and laboratory

Buyer activity

22 indexed notices

Published by this buyer in the last 90 days

Market context

How this notice compares with the current market

Biderra found 455 pharma and laboratory notices from Germany in its rolling 90-day index. 24% publish an estimated value and 52% include at least one indexed deadline. This notice is currently active according to the deadline fields available in the source feed.

Official title versions

TED may publish the same notice title in several official languages. Biderra preserves the versions supplied in the source feed.

What Biderra adds

For notice 728085-2026, Biderra has normalized the contracting authority country as Germany, grouped CPV 33600000 under pharma and laboratory, compared the available deadline fields with today, measured field completeness, and preserved 7 source-supplied title versions. The official record remains decisive.